Solutions to enable diagnosis and treatment of adverse health consequences of non-disordered drug use (R41/R42 - Clinical Trial Optional)

The summary for the Solutions to enable diagnosis and treatment of adverse health consequences of non-disordered drug use (R41/R42 - Clinical Trial Optional) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Solutions to enable diagnosis and treatment of adverse health consequences of non-disordered drug use (R41/R42 - Clinical Trial Optional): This funding opportunity calls for developing novel solutions targeted to improve health outcomes and reduce the impact of adverse health consequences in people who use drugs. These solutions should maximize accessibility and affordability, ideally designed to be implemented in mobile community-based care systems and able to reach the vulnerable and underserved population with limited engagement with conventional healthcare services. Solutions could be based on original technologies or existing technologies already available that could be repurposed to target the specific needs of people who use drugs.

Federal Grant Title:	Solutions to enable diagnosis and treatment of adverse health consequences of non-disordered drug use (R41/R42 - Clinical Trial Optional)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Education, Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-DA-25-049
Type of Funding:	Grant
CFDA Numbers:	93.279
CFDA Descriptions:	Information not provided
Current Application Deadline:	December 2nd, 2024
Original Application Deadline:	December 2nd, 2024
Posted Date:	June 13th, 2024
Creation Date:	June 13th, 2024
Archive Date:	January 7th, 2025
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No
Last Updated:	June 13th, 2024

Applicants Eligible for this Grant: Small businesses
Additional Information on Eligibility: Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
Link to Full Grant Announcement: https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-049.html
Grant Announcement Contact: NIH Grants Information
[email protected]
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
Similar Government Grants: • CCRP Initiative: Promoting a Basic Understanding of Chemical Threats to Skin (R01 Clinical...; • Dynamic and Adaptable Infrastructure for Drug Development and Outreach to Aid the Research...; • Development of Interventions to Prevent and Treat Substance Use Disorders and Overdose (UG...; • Single Source: National Longitudinal Study of Adolescent to Adult (Add) Health Wave VII (U...; • Development and Testing of Novel Interventions to Improve HIV Prevention, Treatment, and P...; • NIDA Phase II Small Business Innovation Research (SBIR [R44]) Competing Renewal Awards; • Drug Abuse Aspects of Hiv/Aids and Other Infections; • Epidemiology of Drug Abuse
More Grants from the National Institutes of Health: • INCLUDE Project: Clinical Trials Phased Awards for Down syndrome Research (R61/R33 Clinica...; • INCLUDE Project: Transformative Research Awards for Down syndrome (R01 Clinical Trial Not ...; • INCLUDE Project: Exploratory/Developmental Research Awards for Down syndrome (R21 Clinical...; • Maximizing Investigators' Research Award (MIRA) for Early Stage Investigators (ESI); • Limited Competition: Small Grant Program for NHLBI K01/K08/K23/K25 Recipients (R03 Clinica...